<DOC>
	<DOC>NCT01440062</DOC>
	<brief_summary>Examination of efficacy, safety and tolerability of vitamin D3 in the treatment of Multiple Sclerosis (MS).</brief_summary>
	<brief_title>Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Informed consent Age between 18 and 65 at randomization Relapsingremitting MS according to the revised McDonaldCriteria (2005) EDSS ≤ 6,0 Stable immunomodulatory treatment for at least 3 months Sufficient birth control (PearlIndex &lt;1) and negative pregnancy test at screening/randomization Any other MScourse than RRMS Treatment with high dose vitamin D within 6 months prior to randomization Patients who have received over the last three months prior to randomization, an immunomodulatory therapy with the exception of IFNβ1b (Betaferon ®) Any condition that could interfere with MRI or other study related investigation Intolerability to GdDTPA Hypersensitivity to the drug Colecalciferol Patients with sarcoidosis Presence or history of nephrolithiasis Pseudohypoparathyroidism Clinically relevant dysfunction of liver, bone narrow or kidney defined by the following laboratory values: HB &lt;8.5 g / dl WBC &lt;2.5 / nl platelet count &lt;100/nl Creatinine clearance by CockcroftGault formula: Cl &lt;110ml/min (male) and Cl &lt;95ml/min (female) AST / ALT&gt; 3.5 times higher than the upper reference value bilirubin&gt; 2.0 mg / dl hypercalcaemia&gt; 2.7 mmol / l calcium / creatinine ratio in urine&gt; 1 Treatment with hydrochlorothiazide, digitoxin, digoxin, phenytoin, barbiturates Pregnancy or lactation period Participation in any clinical study within 3 months before or at any time during study Any medical, psychiatric or other condition that could interfere with the patient's ability to understand and give the informed consent, to comply with the protocol or to finish the study any ruling commitment or placement in an institution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>